Sino Science and Technology Co., Ltd. is a technology enterprise engaged in providing technical services for the development of petroleum, natural gas, and new energy, environmental engineering integrated services, and information software support. The company holds Class A qualifications in six engineering consulting specialties and has obtained Class A qualifications in petroleum, natural gas (offshore oil), as well as Class B qualifications in municipal, power, new energy, and construction industries for engineering design. The company is also qualified in environmental impact assessment for construction projects, engineering cost, project supervision, and engineering surveying. Additionally, it has obtained qualifications for clean production audits, energy audits, energy management system services, and information integration services (CMMI, ITSS), and has passed QHSE management system certification and integration of industrialization and informatization management system certification.
Since its establishment, the company has closely followed national industrial development strategies, fully aligning with the development needs of clients. It focuses on promoting energy-saving, consumption-reduction, and green low-carbon technology research and product services for oil and gas fields and new energy development. The company provides specialized services in management informatization and enterprise intelligence, having completed more than 40,000 consulting projects with an investment totaling nearly 4 trillion RMB. It has helped clients optimize and save over 60 billion RMB in investment.
Bescore is a leading provider of battery storage and charging products, as well as integrated energy and smart microgrid solutions in the clean energy sector.
The company is committed to the independent research, development, production, and sales of battery storage systems and core modules, capable of meeting energy storage needs for residential, commercial, and industrial scenarios. It also manages the application of integrated energy in communities, universities, and other settings, and offers microgrid development, construction, and operation and maintenance services for commercial, rural, and island environments. Our solutions support “emergency backup power”, “self-consumption with surplus power fed back to the grid”, “peak shaving and valley filling”, and contribute to achieving “zero-carbon factories”. Thanks to our engineers and experts with rich knowledge and experience from around the world, we have independently developed BMS, EMS, PCS, and other key technologies.
Founded in 1987, Huawei is a leading global provider of information and communications technology (ICT) infrastructure and smart devices. We have approximately 208,000 employees and we operate in over 170 countries and regions, serving more than three billion people around the world. We are committed to bringing digital to every person, home and organization for a fully connected, intelligent world.
In the transportation sector, Huawei is focusing on laying a digital and intelligent foundation for comprehensive transportation and logistics systems through "transportation hubs, transportation networks, passenger and freight flows, and the lowaltitude economy." Such a foundation will streamline "passenger, logistics, business, fund, and information flows," and support secure and efficient operations across both supply and value chains. We aim to enable "convenient travel and smooth logistics for a digital and intelligent future." We currently serve more than 100 sea and land ports, more than 200 logistics and warehousing companies, more than 300 urban rail lines, and over 180,000 kilometers of railways worldwide. Our solutions also cover over 200,000 kilometers of roads, over 300 urban traffic management organizations and over 210 airports, airlines, and air traffic management organizations around the world.
Nanning Chaofu Electric Technology Co., Ltd. has long been dedicated to the research and application of lightning protection for transmission and distribution lines. The company has developed high-energy dielectric arc-extinguishing lightning protection gap products for 10kV, 35kV, 110kV, and 220kV systems, capable of extinguishing expected power-frequency short-circuit currents up to 40kA with an arc-extinguishing time of <2ms. This series is the only product line in china that has achieved these performance specifications.
The core high-energy dielectric arc-extinguishing, lightning, protection technology was developed by the team led by Professor Wang Jufeng, legal representative of Nanning Chaofu Electric Technology Co., Ltd. and researcher at Guangxi University. It is a fully integrated new lightning protection technology covering theory, R&D, product development, and application, with independent intellectual property rights. The achievement has been evaluated by experts as reaching world-leading level.
The company is the primary drafting organization of the power industry standard "DL/T 2110-2020 Guidelines for Selection of Self-Arc-Extinguishing Parallel Gaps for Lightning Protection of AC Overhead Lines." It has been granted a total of 160 authorized patents, including 35 invention patents, 100 utility model patents, 25 design patents, 2 U.S. patents, 1 Japanese patent, and 1 Australian patent, Chairman Wang Jufeng has received the First Prize of Guangxi Technical invention Award (2013), First Prize of Guangxi Scientific and Technological Progress Award (2015), First Prize of Guangxi Power Grid Scientific and Technological Progress Award (2015), Second Prize of China Southern Power Grid Scientific and Technological Progress Award (2015), and the China Patent Excellence Award (2016). He has also published a monograph on high-energy dielectric arc extinguishing with Science Press.
The high-energy dielectric arc-extinguishing lightning protection gap series has been widely deployed across major state-owned enterprises, including State Grid, China Southern Power Grid, China Huadian Group, Sinopec, and CNPC. Applications cover lightning-prone regions in eight provinces, including Guangxi, Yunnan, Fujian, and Xinjiang, particularly on coastal lines, mountainous lines, and dedicated oilfield power supply lines with the highest lightning strike incidence. Since the products were first installed and operated in 2012 (with three-phase protection), more than 15,000 towers have been equipped at 10kV, over 600 towers at 35kV, more than 500 towers at 110kV, and over 200 towers at 220kV. In total, the protected line corridors exceed 1,000km, achieving the goals of "zero tripping" and "zero line breakage" within the protected sections.
Venus Medtech (Hangzhou) Inc. (hereinafter referred to as "Venus Medtech") was established in 2009 as an innovation-driven high-end medical device company specializing in structural heart disease, headquartered in Hangzhou National High-tech Industrial Development Zone (Binjiang). The company was listed on the Main Board of the Hong Kong Stock Exchange on December 10, 2019, with stock code 02500. It has established global R&D centers in China, the United States, and Israel, forming a globalized R&D, manufacturing, marketing, and service network. The company currently employs approximately 600 people from nearly 10 countries. Venus Medtech is committed to finding effective treatment solutions for major diseases that seriously threaten human health.
Venus Medtech has built a comprehensive structural heart disease solution portfolio covering aortic valve, pulmonary valve, mitral valve, and tricuspid valve diseases, as well as a complete pipeline of surgical accessories. As of November 2025, the company has successfully established a product pipeline centered on "Four-valve in One," including six transcatheter aortic valve replacement (TAVR) products: VenusA-Valve, VenusA-Plus, VenusA-Pro, VenusA-Deluxe, Venus Vitae, and Venus-PowerX; one transcatheter pulmonary valve replacement (TPVR) product VenusP-Valve; two surgical accessories G Sheath expandable introducer sheath and TAV8 balloon dilatation catheter; and an innovative device Cardiovalve that can be used for both transcatheter mitral valve replacement (TMVR) and transcatheter tricuspid valve replacement (TTVR). Currently, Venus Medtech's full series of "Made-in-China" valve products have entered more than 60 countries and regions worldwide, covering Asia, Europe, Australia, Africa, South America, and North America. In 2017, VenusA-Valve became China's first approved TAVR product, filling the gap in domestic transcatheter valve therapy and establishing Venus Medtech as a leader in China's interventional structural heart disease field.
In terms of international business, VenusP-Valve, the world's first and only self-expanding TPVR product approved in both China and Europe, has been approved in nearly 70 countries and regions. As the company's flagship product, it has been included in reimbursement in major European countries, with steady growth in implant volumes. In 2023, it received U.S. FDA Investigational Device Exemption (IDE) approval, becoming the first Chinese-made artificial heart valve approved for clinical trials in the United States. The innovative Cardiovalve tricuspid valve replacement device has completed enrollment in its European confirmatory clinical trial, earning high praise from clinicians for its performance. Interim results from the TARGET study demonstrate excellent safety and clinical efficacy in patients with severe tricuspid regurgitation. The next-generation dry-valve TAVR product Venus-PowerX was approved in Argentina and Chile in 2023, successfully treating multiple Latin American patients and bringing high-quality Chinese cardiac valve solutions to countries along the Belt and Road.
Adhering to pragmatic innovation and consistently accumulating core technologies, Venus Medtech has accumulated over 900 patents (applications), including nearly 800 authorized invention patents, with layouts in major countries and regions including China, the United States, Europe, Japan, Canada, Russia, India, and Brazil. As a leading domestic innovator, Venus Medtech has received numerous honors and awards, including participation in the 12th, 13th, and 14th Five-Year Plan Key R&D Programs initiated by the Ministry of Science and Technology, multiple provincial and ministerial science and technology progress awards, recognition as a second-batch National Specialized, High-end and Innovation-driven "Little Giant" Enterprise, the China Excellent Patent Award, Excellent Domestic Medical Device Product, and National High-tech Enterprise.
Venus Medtech has always been grounded in evidence-based medicine. The clinical value of its core products and solutions has been continuously validated through multicenter studies covering cardiovascular disease, structural heart disease, and congenital heart disease. It has gradually built a multidimensional clinical evidence system across procedures and patient populations, from early feasibility to long-term follow-up, providing scientific decision support for physicians worldwide.
Every advancement at Venus Medtech stems from reverence for life and a commitment to accessible healthcare. Looking to the future, the company will remain true to its original mission of "addressing the needs of society," guided by the core values of "innovation, responsibility, practicability," and pursuing the vision of "Becoming a global leader in structural heart disease." With a more open stance embracing the global market and leveraging established internal and external capabilities, Venus Medtech will continue to focus on clinically value-oriented product innovation, aspiring to become a pillar of China's—and the world's—medical device industry, making "Made in China" a benchmark in global structural heart disease treatment.
Zumax Medical Co., Ltd. was established in 2005 as a private high-tech enterprise specializing in the R&D, production, and sales of surgical microscopes and clinical optical diagnostic instruments. It is a National High-tech Enterprise, a fourth-batch National Specialized, High-end and Innovation-driven "Little Giant" Enterprise, and one of the first enterprises in the new round of National Key "Little Giant" Enterprises. The company is one of the primary drafters of the latest national standard for surgical microscopes and was awarded the 2024 China Patent Award of Excellence.
Adhering to the business philosophy of "Rooted in Technology, Driven by Innovation," the company has, through years of R&D and technological accumulation, developed four core technology platforms — medical microscopic optics, precision mechanics and automation, digital imaging, and surgical navigation — which have been successfully industrialized in its main products.
The company's product portfolio covers clinical specialties including stomatology, neurosurgery, ENT and head & neck surgery, microsurgery, ophthalmology, and gynecology. Its products are exported to more than 100 countries and regions worldwide, progressively breaking the long-standing monopoly of foreign brands in the high-end surgical microscope market and accelerating the localization of premium medical equipment in China.
Shenzhen YHLO Biotech Co., Ltd. (hereinafter referred to as "YHLO") was established in 2008 with a registered capital of RMB 570 million. It is a ChiNext-listed company on the Shanghai Stock Exchange (stock code: 688575). Headquartered in Baolong Technology City, Longgang District, Shenzhen, YHLO is primarily engaged in the R&D, production, sales, and service of in vitro diagnostic (IVD) products in the biomedical industry. It is a National High-tech Enterprise with extensive independent intellectual property rights, a National Intellectual Property Demonstration Enterprise, and has received honors including Guangdong Province Manufacturing Single Champion, First Prize of Shenzhen Science and Technology Progress Award, Top 70 Innovative Enterprises in Shenzhen, and Shenzhen Well-known Brand. In 2023, the Group achieved a total output value of RMB 3.1 billion and paid taxes of RMB 226 million.
YHLO focuses on R&D and innovation in the IVD field, currently operating five major diagnostic technology platforms: chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, and colloidal gold immunochromatography. Its products cover seven business areas: autoimmune diseases, infectious immunology, reproductive health, liver disease detection, routine testing, cardiovascular & cerebrovascular detection, and kidney disease detection. More than 300 products are widely used in hospitals at all levels, township health centers, community clinics, and third-party laboratories, with a coverage rate exceeding 69% in China's top-tier (Grade III) hospitals. While consolidating its domestic market, YHLO actively expands internationally, with products exported to over 120 countries and regions in Europe, the Americas, the Middle East, Southeast Asia, and Africa, earning widespread recognition from global customers.
YHLO adheres to independent innovation, market demand orientation, and customer service as its mission, establishing a complete industry chain from raw material development to R&D, production, and sales. In recent years, YHLO has significantly increased R&D investment, successively establishing R&D centers in Tokyo (Japan), Wuhan, and Changsha, and a production base in Xiangtan, Hunan. Over more than a decade, YHLO has undertaken major national and provincial scientific projects supported by the NDRC, Ministry of Science and Technology, Guangdong Provincial Science and Technology Department, Shenzhen Development and Reform Commission, Science and Technology Innovation Commission, and Industry and Information Technology Bureau. Among them, the project "Development of High-performance Rapid On-site Immunoassay System" led by YHLO and Professor Zhou Zhou from Fuwai Hospital, Chinese Academy of Medical Sciences, was included in the 14th Five-Year Plan National Key R&D Program under the special focus "Diagnostic Equipment and Biomedical Materials." The project "R&D and Industrialization of High-throughput Fully Automated Immunoassay Analyzer and Supporting Reagents" was approved by the NDRC and selected as a Shenzhen Major Project. As of December 31, 2024, the Group has applied for 693 patents, including 64 PCT patents and 410 invention patents (60% of total), with a 75% authorization rate for valid invention patents in the past five years.
The company places great emphasis on industry-academia-research collaboration and talent development, having established joint laboratories with teams led by Academician Zhuang Hui (Peking University), Academician Yan Xiyun (Institute of Biophysics, CAS), Academician Tang Benzhong (The Chinese University of Hong Kong, Shenzhen), Academician Gu Dongfeng (Southern University of Science and Technology), Huazhong University of Science and Technology National Laboratory of Optoelectronics, and the National High-Performance Medical Device Innovation Center. Additionally, YHLO has set up training platforms for innovative medical laboratory talent with The Chinese University of Hong Kong (Shenzhen), Huazhong University of Science and Technology, Xiangtan University, Guangdong Medical University, and Hunan University of Technology, jointly cultivating master's and doctoral students and high-level professionals. As of December 31, 2024, high-quality papers published in authoritative journals worldwide using YHLO diagnostic products exceed 1,080, with a cumulative impact factor of 2,970.
Adhering to the mission of "Focusing on Life and Health, Striving to Benefit Humanity Through Technology," YHLO consistently pursues excellence, continuously providing outstanding products and services for human health, and strives to become a leading enterprise in the immuno-diagnostic field and a global leader in in vitro diagnostics.
Shanghai United Imaging Healthcare Co, Ltd. ("UIH") is a member of the United Imaging Healthcare Technology Group Co., Ltd., which is dedicated to providing, developing and producing high-performance advanced medical imaging, radio.therapy equipment, life science instruments and offering intelligent digital solutions to customers worldwide.
UIH has a world-class talent team including more than 140 scientists with global experience and more than 600 employees with rich R&D and management experience in the medical industry. And 40% of 8.400+ employees are R&D personnel.
UIH has launched over 140 ground-breaking products, including Total-Body PET/CT, HD TOF PET/MR, Whole-body UHF 5TMR, 75cm Ultra-Wide Bore 3.0T MR, 640-slice CT Scanner, and Fully Integrated CT-linac. All core technologies are developed in house and have been globally or nationally recognized for world-leading performance.
UIH products have been installed in over 15,300 medical and research institutes in nearly 90 countries, including the U.S., Italy, Germany, France, India, Australia, New Zealand, Poland, Japan, Korea, Malaysia, the United Arab Emirates, etc. UIH topped China's 2024 market share rankings in the PET/CT, CT and DXR sectors.
Glodon Company Limited is the first A-share listed company in China's construction engineering informatization sector. As a digital construction platform service provider, it offers digital solutions for the entire lifecycle of construction, serving various stakeholders in the industry chain, including management authorities, owners, designers, consultants, contractors, equipment and material manufacturers, as well as sectors such as urban operations, finance, and education.
In 2008, Glodon embarked on its internationalization journey, with a forward-looking vision and global strategy. it has established subsidiaries, offices, and R&D centers in countries and regions such as the United States, United Kingdom, Finland, Sweden, Poland, Singapore, Malaysia, Indonesia, and Hong Kong, targeting key international clients including design institutes, consulting firms, and construction companies.
With subsidiaries in Finland, the UK, and Sweden as the core, it radiates across the European market. Leveraging the regional advantages of subsidiaries in Singapore, Malaysia, Indonesia, and Hong Kong, it drives growth in the Southeast Asian market while expanding into Vietnam, the Philippines, Thailand, the Middle East, and other regions through agency models.
To date, its core international business includes: Glodon Cubicost 5D BIM digital cost solution for cost management enabling one-click import and quantity takeoff with efficiency improvements of over five times; it also promotes deep integration of AI in 5D BIM cost management. Glodon's Gsite construction project management platform, as an integrated management solution, helps project teams break down data silos at construction sites, enhancing collaboration efficiency, reducing costs and risks, and improving project competitiveness. Additionally, it offers globally leading MEP design BIM solution MagiCAD, advanced simulation software and services EQUA, and Shapespark, which holds technological advantages and market potential in architectural rendering
Luoyang Wire Rope Inspection Technology Co., Ltd (hereinafter TCK.W) is a national high-tech enterprise, a double-soft enterprise, and a specialized and special new enterprise in Henan Province, specializing in the research of nondestructive testing technology of ferromagnetic materials. The magnetic memory AI weak magnetic NDT technology is at the international leading level, with 14 national invention patents, 5 international invention patents, 30 utility model patents, a total of 49 patents, and 29 software copyright certificates.
Overcoming the century-old problem of wire rope detection technology, TCK.W has a significant advantage over the existing technology, and is a disruptive cutting-edge technology that changes the rules of the industry game.
TCK.W has solved the three major pain points of hidden dangers, waste and inefficiency, and achieving the goals of safety, economy and efficient management are of great value to safe production, cost reduction and efficiency increase, green environmental protection, and dual carbon goals.
TCK.W series of products have entered the United States, Europe, Japan, South Korea, Singapore and many other countries whose users cover mines, ports, petroleum, steel, cranes, elevators, cable ways, cable-stayed bridges and many other fields.